Medical applications of leukocyte surface molecules - The CD molecules

Molecular Medicine

Volumn 12, Issue 11-12, 2006, Pages 312-316

  Zola, Heddy ^a,b,c  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b Co Operative Research Centre for Diagnostics ^*  (Australia)

^c CHILD HEALTH RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CD20 ANTIGEN; CD4 ANTIGEN; CD40 LIGAND; CD52 ANTIGEN; CELL SURFACE PROTEIN; DACLIZUMAB; EFALIZUMAB; EPRATUZUMAB; GEMTUZUMAB OZOGAMICIN; GLYCOLIPID; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN M; IMMUNOTOXIN; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B4; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY IDEC 131; OKT 3; PERTUZUMAB; PM 81; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALLERGY; AUTOIMMUNE DISEASE; CONFERENCE PAPER; GRAFT REJECTION; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOTHERAPY; INFLAMMATION; LEUKEMIA; LEUKOCYTE; LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, CD; CELL MEMBRANE; HIV INFECTIONS; HUMANS; LEUKEMIA; LEUKOCYTES; LYMPHOMA;

EID: 33947690177     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2006-00081.Zola     Document Type: Conference Paper

References (51)

1. Mak TW, Saunders ME. (2006) The immune response: basic and clinical principles. Elsevier/ Academic Press, Amsterdam.
2. Bernard AR, Boumsell L, Dausset J, Milstein C, Schlossmann SF, eds. (1984) Leucocyte typing: human leucocyte differentiation antigens detected by monoclonal antibodies. Springer, Berlin.
3. Reinherz EL, Haynes BF, Nadler L, Bernstein ID, eds. (1985) Leukocyte typing II. Springer, New York.
4. McMichael AJ, Beverley FCL, Cobbold S et al., eds. (1987) Leucocyte typing III: white cell differentiation antigens. Oxford University Press, Oxford.
5. Knapp W, Dorken B, Gilks W, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK, eds. (1989) Leucocyte typing IV: white cell differentiation antigens. Oxford University Press, Oxford.
6. Schlossman SF, Boumsell L, Gilks W et al., eds. (1995) Leucocyte typing V: white cell differentiation antigens. Oxford University Press, Oxford.
7. Kishimoto T, Kikutani H, von dem Borne AEGK et al., eds. (1997) Leucocyte typing VI: white cell differentiation antigens. Garland Publishing Inc., New York.
8. Mason D, Andre P, Bensussan A et al., eds. (2002) Leucocyte typing VII. Oxford University Press, Oxford.
9. Zola H, Swart B, Nicholson I et al. (2005) CD molecules 2005: human cell differentiation molecules. Blood 106:3123-6.
10. Zola H, Swart BW. (2003) Human leucocyte differentiation antigens. Trends Immunol. 24:353-4.
11. Zola H, Swart B, Nicholson I, Voss E. (2006, in press) Leukocyte and stromal cell molecules: the CD markers. Wiley, New York.
12. Nicholson I, Mavrangelos C, Fung K et al. (2005) Characterization of the protein composition of peripheral blood mononuclear cell microsomes by SDS-PAGE and mass spectrometry. J. Imm. Meths. 305:84-93.
13. Vignali DAA. (2000) Multiplexed particle-based flow cytometric assays. J. Imm. Meths. 243:243-55.
14. Liu W, Putnam A, Xu-yu Z et al. (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+T reg cells. J. Exp. Med. 203:1701-11.
15. Garcia JF, Mollejo M, Fraga M. (2005). Large B-cell lymphoma with Hodgkin's features. Histopathogy 47:101-10.
16. Aubrey N, Muzard J, Peter JC, Rochat H, Goyffon M, Devaux C, Billiald P. (2004) Engineering of a recombinant Fab from a neutralizing IgG directed against scorpion neurotoxin AahI, and functional evaluation versus other antibody fragments. Toxicon 43:233-41.
17. Feldmann M, Maini RN. (2001) Anti-TNFa therapy of rheumatoid arthritis: what have we learned? Ann. Rev. of Immun. 19:163-96
18. Buske C, Weigert O, Dreyling M, Unterhalt M, Hiddemann W. (2006) Current status and perspective of antibody therapy in follicular lymphoma. Haematologica 91:104-12.
19. Peterson JW, Comer JE, Noffsinger DM et al. (2006) Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergisric with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Inf. and Immun. 74:1016-24.
20. Gray JC, Johnson PW, Glennie MJ. (2006). Therapeutic potential of immunostimulatory monoclonal antibodies. Clin. Sci. 111:93-106.
21. Kukreja A, Cost G, Marker J et al. (2002) Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest. 109:131-40.
22. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree MIM. (2005) Defective suppressor function in CD4+CD25+ T-Cells from patients with Type 1 diabetes. Diabetes 54:92-9.
23. Vitetta ES, Ghetie VF. (2006) Considering therapeutic antibodies. Science 313:308-9.
24. Rastetter W, Molina A, White CA. (2004) Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu. Rev. Med. 55:477-503.
25. Hagenbeek A. (2003) Radioimmunotherapy for NHL: experience of 90Y-ibrirumomab tiuxetan in clinical practice. Leuk. Lymphoma 44 Suppl 4:837-47.
26. Vose JM. (2004) Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. Oncologist 9:160-72.
27. Grossbard ML, Multani PS, Freedman AS et al. (1999) A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. Clin. Cancer Res. 5:2392-8.
28. Coleman M, Goldenberg DM, Siegel AB et al. (2003) Epratuzumab: targeting B-cell malignancies through CD22. Clin. Cancer Res. 9:3991-45.
29. Keating M, Coutre S, Rai K et al. (2004) Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin. Lymphoma 4:220-7.
30. Wiland AM and Philosophe B. (2004) Daclizumab induction in solid organ transplantation. Expert Opin. Biol. Ther. 4:729-40.
31. Chapman TM, Keating GM. (2003) Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs 63:2803-35.
32. Lo-Coco F, Cimino G, Breccia M et al. (2004) Gentuzumab ozogamicin ("mylotarg") as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 104:1995-9.
33. Ball ED, Selvaggi K, Hurd D et al. (1995) Phase I clinical trial of serotherapy in patients with acute myeloid leukemia with an immunoglobulin M monoclonal antibody to CD15. Clin. Cancer Res. 1:965-72.
34. Pegram MD, Pienkowski T, Northfelt DW, et al. (2004) Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J. Natl. Cancer Inst. 19:759-69.
35. Nahta R, Hung MC, Esteva FJ. (2004) The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 64:2343-6.
36. Richman CM, DeNardo SJ. (2001) Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies. Crit. Rev. Oncol. Hematol. 38:25-35.
37. Brooks D, Taylor C, Dos SB et al. (1995) Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6. Clin. Cancer Res. 1:1259-65.
38. Blumenthal RD. (2004) Technology evaluation: cT84.66, City of Hope. Curr. Opin. Mol. Ther. 6:90-5.
39. Chatenoud L, Bach JF. (1993) Therapeutic monoclonal antibodies in transplantation. Transplant. Proc. 25:473-4.
40. Gottlieb A, Lebwohl M, Shirin S et al. (2000) Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: Results of a pilot, multicenter, multiple-dose, placebo-controlled study. Amer. Acad. of Dermatol. 43:595-604.
41. Dubertret L, Sterry W, Bos JD et al. (2006) Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Brit. J. Dermatol. 155:170-81.
42. Edwards JCW, Szczepanski L, Szechinski J et al. (2004) Efficacy of B-cell-targeted therapy with Rituximab in patients with rheumatoid arthritis. New England J. Med. 350:2572-81.
43. Waldmann TA, O'Shea J. (1998) The use of antibodies against the IL-2 receptor in transplantation. Curr. Opin. Immunol. 10:507-12.
44. Dick AD, Meyer P, James T, Forrester JV, Hale G, Waldmann H, Isaacs JD. (2000) Campath-1H therapy in refractory ocular inflammatory disease. Br. J. Ophthalmol. 84:107-9.
45. Kuwana M, Nomura S, Fujimura K et al. (2004) Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 103:1229-36.
46. Brekke OH, Sandlie I. (2003). Therapeutic antibodies for human disease at the dawn of the twenty-first century. Nature Reviews Drug Discovery. 2:52-62.
47. Teeling JL, French RR, Cragg MS et al. (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104:1793-800.
48. Glennie MJ, Johnson PWM. (2000) Clinical trials of antibody therapy. Immunol. Today. 21:403-10.
49. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. (2006) Immunotoxin therapy of cancer. Nature Reviews Cancer. 6:559-65.
50. Cardarelli RM, Quinn M, Buckman D et al. (2002) Binding to CD20 by Anti-B1 Antibody of F(ab′)2 is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol. Immunother. 51:15-24
51. Teeling JL, Mackus WJM, Wiegman LJJM et al. (2006) The Biological Activity of Human CD20 Monoclonal Antibodies is linked to unique Epitopes on CD201. J. of Immunol. 177:362-71.